is an immunology-driven innovator leveraging a proprietary, AI-powered R&D platform to develop transformative therapies for immune-mediated inflammatory diseases.
Key Milestones
-
Feb 2026TL-001 & TL-003
NewCo Established -
April 2026
TL-003 Ph1
First Subject Dosed -
Oct & Nov 2025
A & A+ Financing
$35M Completed -
April 2025
TL-001 Ph1
First Subject Dosed -
Dec 2024
Pre-A Financing
$16.5M Completed -
Jan 2024
Angel Financing
$1.5M Completed
A Portfolio Shaped by Immunological and Translational Insight
-
TL-0011TL1A HLE mAbUC, CD, and other TL1A-relevant indications
- Discovery
- IND
- Ph1
- Ph2
- Ph3
-
TL-0031TL1A x IL23p19 HLE BsAbUC, CD, etc.
- Discovery
- IND
- Ph1
- Ph2
- Ph3
-
TL-021TL1A x α4β7 HLE BsAbUC, CD, and other TL1A-relevant indications
- Discovery
- IND
- Ph1
- Ph2
- Ph3
-
TL-007TL1A x IL23p19 x α4β7 HLE Trispecific AbUC, CD, etc.
- Discovery
- IND
- Ph1
- Ph2
- Ph3
-
TL-009TACI x IFNAR1 HLE BsAbSLE, CLE, LN, etc.
- Discovery
- IND
- Ph1
- Ph2
- Ph3
-
TL-023TACI HLE Fusion ProteinIgAN, SLE, LN, etc.
- Discovery
- IND
- Ph1
- Ph2
- Ph3
-
TL-008IL23p19 x α4β7 x TNFα HLE Trispecific AbUC, CD, etc.
- Discovery
- IND
- Ph1
- Ph2
- Ph3
-
TL-002OSMR HLE mAbPrurigo nodularis, Pruritus, etc.
- Discovery
- IND
- Ph1
- Ph2
- Ph3
-
TL-TBD2TBDTBD
- Discovery
- IND
- Ph1
- Ph2
- Ph3
- Discovery
- IND
- Ph1
- Ph2
- Ph3
- Partner
-
TL-0011TL1A HLE mAbUC, CD, and other TL1A-relevant indications
-
TL-0031TL1A x IL23p19 HLE BsAbUC, CD, etc.
-
TL-021TL1A x α4β7 HLE BsAbUC, CD, and other TL1A-relevant indications
-
TL-007TL1A x IL23p19 x α4β7 HLE Trispecific AbUC, CD, etc.
-
TL-009TACI x IFNAR1 HLE BsAbSLE, CLE, LN, etc.
-
TL-023TACI HLE Fusion ProteinIgAN, SLE, LN, etc.
-
TL-008IL23p19 x α4β7 x TNFα HLE Trispecific AbUC, CD, etc.
-
TL-002OSMR HLE mAbPrurigo nodularis, Pruritus, etc.
-
TL-TBD2TBDTBD
1 TrueLab retains rights in Greater China, including Mainland China, Hong Kong SAR, Macau SAR, and Taiwan.
2 TBD, to be disclosed. TrueLab has initiated another 10+ programs targeting promising biology pathways.
TrueForgeTM Discovery Engine
TrueForgeTM is an integrated R&D platform that converges translational science, advanced antibody engineering, and generative AI to redefine drug discovery.
Our ecosystem enables the data-driven evolution of therapeutic programs, utilizing machine learning to streamline the identification of novel targets and the precision design of diverse antibody modalities.
By synthesizing multi-omic biological data, TrueForgeTM prioritizes molecules with best-in-class potential, optimizing their molecular properties from binding affinity to enhanced pharmacokinetic profiles for superior clinical performance.
We bridge the gap between initial biological insight and transformative patient outcomes through our unified, AI-enhanced discovery framework.
Press Release
-
E-Mail
-
Business development:
-
Investors & Media:
-
General Inquiries:
-
-
Address
-
Shanghai Headquarter Office
Room 1506, 15th Floor, Tower 1, Jing'an Kerry Centre Office Building, Jingan District, Shanghai, China
-
Suzhou R&D Center
Room 209, Building B1, Biobay, Wuzhong District, Suzhou, Jiangsu, China
-